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Abstract
Background: Coagulation can be visualised using whole blood coagulation analyses such as thromboelastometry
and platelet aggregation tests; however, the role of temperature in the analyses is ambiguous. The aim was to
examine whether temperature influences the whole blood coagulation tests.
Methods: We included 40 patients treated with targeted temperature management (33 ± 1 °C) after out-of-hospital
cardiac arrest. The blood samples were obtained on hypothermia and normothermia. Each blood sample was
analysed simultaneously at 33 °C and 37 °C by thromboelastography (ROTEM®) employing the assays EXTEM®,
INTEM®, FIBTEM® and HEPTEM®, and by Multiplate®Analyzer, using COLtest®, ADPtest®, ASPItest® and TRAPtest® as
agonists. Data on antithrombotic drugs were collected systematically from medical records, and data were analysed
using repeated measurement analysis of variance (ANOVA).
Results: The ROTEM® analyses showed increased clotting time, lower maximum velocity and increased time to
maximum velocity (all p values <0.02) when performed at 33 °C compared with 37 °C, irrespective of the patients
being hypothermic (median 33.1 °C) or normothermic (median 37.5 °C). However, EXTEM® time to maximum velocity
showed no difference between the analyses performed at 33 °C and 37 °C when the patients were hypothermic (p= 0.83).
No differences were found in maximum clot firmness (all p values >0.09) analysed at 33 °C and 37 °C, independent of the
body temperature.
In the hypothermic blood sample, no difference was found when using the COLtest®, ASPItest® or TRAPtest® to compare
platelet aggregation analysed at 33 °C and 37 °C (all p values >0.19), but platelet aggregation was significantly higher
using the ADPtest® (p< 0.001) when analysed at 33 °C. In the normothermic blood sample, the TRAPtest® showed no
difference (p = 0.73) when performed at 33 °C; however, significantly lower aggregation was found using the COLtest® and
ASPItest® (all p values <0.001), while a higher aggregation at 33 °C was found using the ADPtest® (p= 0.003).
Conclusion: ROTEM® analyses seemed not to be dependent on body temperature but showed a slower initiation of
coagulation when analysed at 33 °C compared with 37 °C. The Multiplate®Analyzer results were dependent on the
temperature used in the analyses and the body temperature. In whole blood coagulation tests, the temperature used in
the analyses should be kept at 37 °C irrespective of the patient’s body temperature being 33 °C or 37 °C.
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Background
Severe cerebral damage is frequently observed in survivors
of cardiac arrest [1]. However, the extent of the damage
may be reduced by treating the patients with targeted
temperature management [2, 3]. Evidence from trauma
and surgical patients shows that unintended hypothermia
is associated with an increased risk of bleeding [4–11].
Thus, it appears that targeted temperature management
impairs haemostasis.
The dynamic coagulation process can be visualised by
thromboelastometry (ROTEM®/TEG®), which is used in
bleeding patients [12]. Platelet aggregation can be
evaluated by several methods, but assessment by im-
pedance aggregometry employing the Multiplate®Ana-
lyzer [13] is increasingly common. Analyses involving
both thromboelastometry and Multiplate®Analyzer are
performed at 37 °C, irrespective of the patient’s body
core temperature. This implies that impaired haemo-
stasis may be overlooked in hypothermic patients.
We hypothesised that whole blood coagulation, evalu-
ated by ROTEM® and Multiplate®Analyzer, would reveal
impaired haemostasis in patients treated with targeted
temperature management after cardiac arrest, analysed
at 33 °C instead of 37 °C. Our aim was to examine
ROTEM® and Multiplate®Analyzer measurements ana-
lysed simultaneously at 33 °C and 37 °C in patients
treated with targeted temperature management after
cardiac arrest.
Methods
This study was a prospective cohort study conducted
from March 2013 to March 2014 at the Intensive Care
Unit of Aarhus University Hospital, Denmark. It is a
sub-study of the trial entitled “Time-differentiated
Therapeutic Hypothermia” (ClinicalTrials.gov Identifier:
NCT01689077). In this study, comatose patients resusci-
tated after cardiac arrest were randomised to either
24 hours or 48 hours of target temperature management
(33 ± 1 °C). Inclusion criteria were as follows: return of
spontaneous circulation (ROSC) after out-of-hospital
cardiac arrest of presumed cardiac cause, Glasgow Coma
Score <8, and age ≥18 years and <80 years. The exclu-
sion criteria were the following: >60 minutes from circu-
latory collapse to ROSC, time interval >4 hours from
cardiac arrest to initiation of target temperature manage-
ment, terminal illness, coagulation disorder, unwitnessed
asystolia, cerebral performance category 3–4 before the
cardiac arrest, pregnancy, persistent cardiogenic shock
(systolic blood pressure <80 despite inotropic treatment),
new apoplexy or intracerebral haemorrhage, or lack of
consent. Written informed consent was obtained from
the relatives and from the patients themselves if they be-
came capable of signing informed consent. The Danish
Data Protection Agency and the Central Denmark
Region Committees on Health Research Ethics approved
the study (case number 20110022), and the study was
performed in accordance with the Helsinki Declaration.
We included 40 patients resuscitated after out-of-
hospital cardiac arrest, 5 of whom have previously been
described by Nielsen et al. [14]. A medical doctor arriving
by ambulance in a pre-hospital setting treated the patients
prior to arrival at hospital. The pre-hospital protocol
instructed the doctor to initiate cooling using intravenous
NaCl (30 ml/kg) at 4 °C. All patients were treated with
targeted temperature management for either 24 hours or
48 hours using surface cooling or intravascular cooling,
and the patients were subsequently rewarmed at a rate of
0.5 °C/hour. Sedation during targeted temperature man-
agement was achieved by intravenous administration of
remifentanil and propofol.
The body core temperature upon admission was
measured in the ear or in the bladder, whereas the body
core temperature at the intensive care unit was
measured continuously in the bladder. If the patient had
been discharged to the ward at the time of the normo-
thermic blood sample, the body core temperature was
measured as rectal temperature.
Information about the use of antithrombotic drugs
was collected from the patients’ medical records. “No
ADP inhibitors” referred to patients with no use of ad-
enosine diphosphate receptor inhibitors (ADP inhibitors)
at any time points, and “with ADP inhibitors” referred to
patients who used APD inhibitors 24 hours prior to obtain-
ing the blood sample. A similar distinction was made in re-
lation to the use of aspirin; “no aspirin” meaning no aspirin
treatment at any time point and “with aspirin” meaning
treatment 24 hours prior to obtaining the blood sample.
Blood samples
The first blood sample was obtained upon admission to
hospital, the second after 22 ± 2 hours of targeted
temperature management (the hypothermic blood sample),
and the third at normothermia 48 ± 2 hours later (the nor-
mothermic blood sample). Blood samples were drawn from
an arterial line or collected from the cubital vein or a cen-
tral venous catheter using a 21G needle. At hypothermia
and normothermia, citrate (3.2 %) blood collecting tubes
were used for thromboelastometry (ROTEM®, Tem
International GmbH, Munich, Germany), employing the
assays EXTEM®, INTEM®, FIBTEM® and HEPTEM® (Tem
International GmbH, Munich, Germany), coefficient of
variation for all parameters <15 %. Hirudine anticoagulant
tubes were used for platelet aggregation tests (Multipla-
te®Analyzer, Roche, Diagnostics GmbH, Mannheim,
Germany); and the COLtest®, ADPtest®, ASPItest® and
TRAPtest® were used as agonists (Roche, Diagnostics
GmbH, Mannheim, Germany); the coefficient of variation
for all parameters was ≤15 %.
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Blood samples for ROTEM® and Multiplate®Analyzer
were immediately transferred to the preheating station
of the apparatus. The temperature of the preheating
station was adjusted to the chosen analysis temperature.
The samples were rested for 30 minutes at the antici-
pated analysis temperature before initiating the analyses
simultaneously at 33 °C and 37 °C, respectively. Clotting
time, maximum velocity, time to maximum velocity and
maximum cloth firmness were derived from the
ROTEM® results. For the Multiplate®Analyzer results,
the area under the curve (AUC, AU*min) was used as an
indication of platelet aggregation.
Upon admission, on drawing the hypothermic blood
sample and the normothermic blood sample, the platelet
and white blood cell counts were analysed using an XE-
5000 haematology analyser (Sysmex, Kobe, Japan). The
international normalised ratio (INR) and fibrinogen
(functional) were analysed employing the CS2100i
(Sysmex, Kobe, Japan). Blood pH, lactate, and calcium
were analysed using ABL800 FLEX (Radiometer,
Brønshøj, Denmark).
Samples for the C-reactive protein (CRP) were obtained
within 12 hours (90 % within 4 hours) from the blood
sample obtained at admission, on hypothermia or on
normothermia. CRP was analysed using the Cobas6000
(Roche, Mannheim, Germany).
Statistics
We chose a minimally relevant difference of 6 seconds
in ROTEM®, EXTEM® clotting time, and a 30 AU*min
difference in the Multiplate®Analyzer, COLtest® when
comparing paired samples obtained at 37 °C with samples
obtained at 33 °C during target temperature management.
We knew neither the mean nor the standard deviation for
patients treated with target temperature management, and
we therefore performed the power calculations for
ROTEM® analyses based on data from patients with sepsis
(EXTEM® mean clotting time of 65 seconds and standard
deviation = 10 [15]) and for Multiplate®Analyzer analyses
based on healthy individuals (COLtest® mean AUC of
853 AU*min and standard deviation = 53 (data from
Rubak et al. [16])). To achieve statistical power of 90 %
and a two-sided significance level of 5 %, we had to
include 32 patients for the ROTEM® analyses and 35
patients for the Multiplate®Analyzer to identify the chosen
minimally relevant difference.
The observations were not normally distributed and
therefore data are described as counts, percentages or as
medians with ranges. However, inspection of the resid-
uals revealed no deviation from normality, therefore data
were analysed using repeated measurements analysis of
variance (ANOVA). Using ANOVA, we compared re-
sults obtained at 33 °C with results performed at 37 °C.
Additionally, to evaluate whether the patient body core
temperature interacted with the results, we tested whether
the difference between analyses performed at 33 °C and
37 °C in the hypothermic blood sample was equal to the
difference between analyses performed at 33 °C and 37 °C
in the normothermic blood sample. The temperature used
for the analyses and the body core temperatures were
categorised. Data from the ANOVA are presented as
means with 95 % confidence intervals (CIs).
The Wilcoxon-Mann-Whitney test was used to com-
pare patients treated with 24 hours versus 48 hours of tar-
get temperature management in both the hypothermic
and the normothermic blood sample. Data were analysed
using STATA® version 13 (StataCorp LP, College Station
TX, USA).
Results
Forty patients were included in the study, but five
patients had missing ROTEM® or Multiplate®Analyzer
values: two patients died, one patient was moved to an-
other facility before the last sample was obtained, and
two patients had missing values due to technical error.
There were 21 patients randomized to 24 hours of
hypothermia and 19 patients to 48 hours of hypothermia.
Among the 40 patients included in the data analyses, 35
patients were male, and the median age was 61 years. The
vast majority (93 %) received bystander cardiopulmonary
resuscitation and 85 % primarily had a shockable rhythm.
Approximately half of the patients were treated with per-
cutaneous coronary intervention. Almost half the patients
received ADP inhibitors and one received both ticagrelor
and clopidogrel prior to obtaining the hypothermic blood
sample. No patients received non-vitamin K oral anticoag-
ulants. The baseline characteristics of the study population
are shown in Table 1, 2 and 3.
On conventional coagulation laboratory investigations
upon admission the majority of haemoglobin and plate-
let counts were within the normal range, but the white
blood cell count was above the normal range. The
fibrinogen was within the normal range, but on normo-
thermia the majority of patients had a value above the
normal range. The CRP was within the normal range
upon admission but increased and was above the normal
range in both the hypothermic and the normothermic
blood sample. Most patients were still acidotic when
they were admitted to the intensive care unit, but pH
was within the normal range on hypothermia.
For the hypothermic blood sample, the median body
core temperature was 33.1 °C (range 32.6–34.4 °C); for
the normothermic blood sample, the median body
temperature was 37.5 °C (range 35.8–38.3 °C). The body
core temperature was collected in 34 patients (85 %)
within 1 hour from collection of the admission blood
sample. The median body core temperature at admission
was 34.5 °C (range 32.5–37.3 °C).
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ROTEM®
No differences in the ROTEM® results were found
between patients using aspirin, low molecular-weight hep-
arin (LMWH) or ADP inhibitors. In three patients using
warfarin prior to the cardiac arrest, EXTEM® results
performed at 37 °C in the hypothermic blood sample had
a prolonged clotting time varying from 96–144 seconds;
and time to maximum velocity varied from 154–183 sec-
onds. These results were confirmed by an INR varying
from 3.8–4.5 at the same time points in the same patients.
The patients on warfarin deviated from the other patients
by having a very large difference between EXTEM® clot-
ting time performed at 33 °C compared with 37 °C. The
EXTEM® clotting time in these three patients was 32–44
seconds longer in the analyses performed at 33 °C. Thus,
patients on warfarin were omitted from the analyses of
the difference between results for 33 °C and 37 °C in
EXTEM® clotting time and time to maximum velocity.
The ROTEM® results that were performed at 33 °C and
compared with 37 °C, showed an increasing clotting time
(all p values ≤0.001), decreasing maximum velocity
(all p values ≤0.001) and an unchanged maximum clot
firmness (all p values ≥0.15) (Table 4 and Fig. 1). We com-
pared the difference between ROTEM® analyses performed
at 33 °C and 37 °C in the hypothermic blood sample with
the difference between ROTEM® analyses performed
at 33 °C and 37 °C in the normothermic blood sam-
ple. We found no significant difference in clotting time,
time to maximal velocity, maximum velocity, or maximum
clot firmness (all p values ≥0.45). However, a significant dif-
ference was found in EXTEM® time to maximum velocity
(p = 0.002).
The HEPTEM® results were similar to the INTEM®
results; this was supported by an INTEM®/HEPTEM®
clotting time ratio of 1.0.
Multiplate®Analyzer
The difference between Multiplate®Analyzer analyses
performed at 33 °C and 37 °C in the hypothermic blood
sample were significantly different from the difference
between Multiplate®Analyzer analyses performed at 33 °C
and 37 °C in the normothermic blood sample in the COLt-
est® (p = 0.05) and the ASPItest® (p = 0.02): there were no
differences in either test in the Multiplate®Analyzer results
performed at 33 °C and 37 °C when the patients were
hypothermic (COLtest® p = 0.79; ASPItest® p = 0.43); how-
ever, in the normothermic patients, there was decreased ag-
gregation at 33 °C (COLtest® p < 0.001, ASPItest® p < 0.001)
(Table 5 and Fig. 2).
On the ADPtest® there was increased aggregation when
analysed at 33 °C compared with 37 °C in hypothermic pa-
tients, and in normothermic patients who were not given
ADP inhibitors (all p values <0.02). The TRAPtest® was not
dependent on the temperature of the analyses or the body
core temperature (all p values ≥0.18) (Table 5 and Fig. 2).
Duration of hypothermia
In the hypothermic blood sample, the EXTEM® max-
imum velocity was longer (p = 0.02) in the 48-hour
Table 1 Baseline characteristics
Variables Values
Number of patients, total (%) 40 (100)
Age, years 61 (range 23–79)
Sex, male 35 (88)
Bystander cardiopulmonary resuscitation 37 (93)
Primary rhythm
Ventricular tachycardia/fibrillation 34 (85)
Asystole, pulseless electrical activity 6 (15)
ROSCa, minutes 17.5 (range 5–40)
Coronary angiography 38 (95)
Percutaneous coronary intervention 19 (48)
SAPS II 50 (range 35–75)
Comorbidity, all/n (%) 40 (100)
Hypertension 19 (48)
Hyperlipidaemia 13 (33)
Previous acute myocardial infarction 9 (23)
Atrial fibrillation 3 (8)
Diabetes 8 (20)
Chronic obstructive pulmonary diseases/asthma 4 (10)
Characteristics of 40 patients treated with targeted temperature management
after cardiac arrest. Results are presented as number of patients (%), or
median (range)
ROSC return of spontaneous circulation, SAPS II Simplified Acute Physiology
Score II, CRP C-reactive protein
aTime from cardiac arrest to ROSC







Medication, all/n (%) 40 (100) 40 (100) 37 (100)
Adenosine diphosphate
receptor inhibitor, all:
3 (8) 19 (48) 16 (43)
Ticagrelor 2 (5) 14 (35) 14 (38)
Clopidogrel 1 (3) 6 (15) 2 (5)
Aspirin 15 (38) 29 (73) 25 (68)
Bivalirudinb 0 (0) 12 (30) 0 (0)
Low molecular-weight
heparin
0 (0) 28 (70) 29 (78)
Unfractionated heparin 0 (0) 19 (48) 0 (0)
Warfarin 3 (8) 0 (0) 1 (3)
Characteristics of 40 patients treated with targeted temperature management
after cardiac arrest. Results are presented as number of patients (%), or
median (range)
aMedication given 24 hours prior to blood sample collection
bUse of bivalirudin ended 16–20 hours before obtaining the hypothermic
blood sample.
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group. In the normothermic blood sample, we found a
longer INTEM® clotting time and time to maximum vel-
ocity (all p < 0.02) in the 48-hour group. Besides these
differences, the ROTEM® and Multiplate®Analyzer re-
sults were comparable in the two intervention groups in
both the hypothermic and the normothermic blood
samples.
Discussion
We conducted a prospective study with paired observa-
tions on hypothermia and subsequent normothermia to
investigate whether ROTEM® and Multiplate®Analyzer
results were temperature-dependent. With ROTEM®
there was compromised initiation of coagulation when
analysis was performed at 33 °C, but no differences in
maximum clot firmness. The ROTEM® results did not
appear sensitive to the patient’s body core temperature.
The Multiplate®Analyzer measurements were influenced
by the temperature of the analyses and by the patient’s
body core temperature, but in different ways depending
on the agonist used.
Previous studies have investigated whether the
temperature of the analyses influenced the thromboelas-
tometric measurements. However, these studies included
only small sample sizes and were carried out in vitro in
samples from normothermic healthy individuals [17–19]
or in hypothermic patients [20–22]. Our ROTEM® results
are in accordance with those reported in these previous,
smaller studies, and they indicate prolonged clotting initi-
ation and no difference in clot strength when performed
at 33 °C, and compared with 37 °C. To our knowledge, no
previous studies have examined whether this impairment
is reduced when the patients are rewarmed. We therefore
investigated whether the difference between analyses per-
formed at 33 °C and 37 °C would be the same for
hypothermic and normothermic patients.
Table 3 Conventional coagulation laboratory investigations
Laboratory investigations (normal range) Upon admission 40 (100) On hypothermia 40 (100) On normothermia 37 (100)
Haemoglobin, mmol/l (8.3–10.5) 8.5 (5.7–10.7) 8.1(5.4–10.4) 7 (5.6–9.1)
Platelet count, 10^9/l (145–350) 193 (121–482) 163 (98–399) 142 (57–281)
White blood cell count, 10^9/l (3.5–10.0) 13.4 (4.9–44.6) 9.3 (2.9–22.0) 9.3 (5.2–18.1)
Fibrinogen, functional, μmol/l (5.5–12.0) 6.7 (3.2–12.5) 9.2 (4.5–14.8) 13.3 (7.9–25.9)
International normalised ratio (<1.2) 1.2 (<1– > 10) 1.1 (1.0–4.5) 1.2 (1.1–2.3)
CRP, mg/ml (<8.0) 2.0 (<0.6–76.6) 57.0 (3.1–159.3) 136.7 (10.0–454.0)
Ph (7.37–7.45) 7.26 (7.07–7.43)a 7.38 (7.18–7.47) -
Lactate, mmol/l (0.5–2.5) 2.3 (0.4–12.6)a 1.4 (0.6–7.0) -
Ca2+, mmol/l (1.18–1.32) 1.07 (0.94–1.41)a 1.17 (1.05–1.59 -
Characteristics of 40 patients treated with targeted temperature management after cardiac arrest. Results are presented as number of patients (%), or median (range)
aUpon admission to the intensive care unit
Table 4 The difference in ROTEM® results performed at 33 °C and 37 °C in 40 cardiac arrest patients
Hypothermia (body core temp median 33.1 °C), n = 39
ROTEM® 33 °C versus 37 °C
Normothermia (body core temp median 37.5 °C), n = 36
ROTEM® 33 °C versus 37 °C
Mean difference (95 % CI) P value Mean difference (95 % CI) P value
EXTEM®
Clotting time, sec 8 (4; 12) <0.001 9 (5; 13) <0.001
Maximum velocity, mm/sec –4 (–4; -3) <0.001 –4 (–5; –3) <0.001
Time to maximum velocity, sec 2 (–12; 15) 0.82 17 (2; 33) 0.03
Maximum clot firmness, mm 0 (–1; 0) 0.15 0 (–1; 0) 0.27
INTEM®
Clotting time, sec 27 (20; 34) <0.001 28 (20;36) <0.001
Maximum velocity, mm/sec –5 (–6; –4) <0.001 –4 (–5; –4) <0.001
Time to maximum velocity, sec 32 (19; 45) <0.001 33 (19; 47) <0.001
Maximum clot firmness, mm 0 (–1; 0) 0.31 0 (–1; 1) 0.98
FIBTEM®
Maximum clot firmness, mm 1 (–1; 3) 0.41 0 (–2; 2) 0.70
temp temperature, n number, CI confidence interval
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We found that patients using warfarin had a very
long clot formation time, which is consistent with
INR above the usual therapeutic range. Notably, in
these patients treated with warfarin we observed a
very large difference in EXTEM® clotting time
between analyses performed at 33 °C and 37 °C. The
present study included only patients with no pre-
existing bleeding disorders; as such, we do not know
whether there would be a large difference between





















Hypothermic patients Normothermic patients























Hypothermic patients Normothermic patients

























Hypothermic patients Normothermic patients




















Hypothermic patients Normothermic patients



















Hypothermic patients Normothermic patients
























Hypothermic patients Normothermic patients
























Hypothermic patients Normothermic patients





















Hypothermic patients Normothermic patients





















Hypothermic patients Normothermic patients
P = 0.41 P = 0.70
Fig. 1 Box plots of ROTEM® results analysed at 33 °C and 37 °C. Forty cardiac arrest patients were included in the study. There were 39 hypothermic samples
and 36 normothermic samples included in the ROTEM® analyses. The p value is for comparison of results of ROTEM® performed at 33 °C and at 37 °C
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with pre-existing impaired haemostasis, as was seen
in patients treated with warfarin.
The Multiplate®Analyzer was used in three previous
studies to investigate the ability of platelets to aggregate
during hypothermia [23–25]. Two of these studies were
performed in vitro [23, 24], and the third investigated
the difference between haemostasis in hypothermia and
in subsequent normothermia [25]. All three studies
were small and there was no difference between ana-
lyses performed at 33 °C and at 37 °C, except in the
study by Kander et al. who demonstrated a significant
difference using the ASPItest® in normothermic pa-
tients [25], which is in accordance with our ASPItest®
results. However, our ADPtest® and COLtest® results
differed from the results reported in previous studies,
probably because the previous studies were under-
powered due to the large standard deviation in the
Multiplate®Analyzer results.
We observed that platelet aggregation sensitivity to
hypothermia had different patterns dependingt on the
agonist used; however, the reason for this remains unre-
solved. We observed decreased platelet aggregation
using the COLtest® and the ASPItest® when analysing
normothermic blood at 33 °C. However, there was more
aggregation at 33 °C using the ADPtest®. There was also
increased platelet aggregation in other studies when plate-
lets were stimulated with ADP on hypothermia [26, 27].
Whether there is increased or decreased platelet aggrega-
tion during target temperature management is intensely
debated, especially in patients with a risk of stent throm-
bosis after percutaneous coronary intervention [28–31].
The COLtest® and ASPItest® results were not affected
in the hypothermic blood sample, but we observed a
difference in the normothermic blood samples. Thus,
targeted temperature management might inhibit the
COLtest® and ASPItest®, but rewarming the blood
sample for 30 minutes at the preheating station did not
terminate the inhibition.
In clinical practice, ROTEM® and Multiplate®Analyzer
analyses are performed at 37 °C. However, by measur-
ing the results at 37 °C instead of 33 °C in patients
treated with targeted temperature management, we
overlooked a small compromised initiation and propa-
gation of the coagulation using ROTEM®. With the
Multiplate®Analyzer we overlooked a small increased
aggregation using the ADPtest®. It is doubtful, how-
ever, whether these rather small differences in
ROTEM® and Multiplate®Analyzer have any clinical
impact. Therefore, we recommend maintaining the
practice of analysing whole blood coagulation tests at
37 °C, irrespective of whether the patient’s body core
temperature is 33 °C or 37 °C.
The strength of this cohort study is that it involves a
large sample size with paired data obtained on both
hypothermia and subsequent normothermia. The study
included patients with cardiac arrest, which increased
the external validity for study of critically ill patients.
Moreover, there was a small time frame for each sampling
and the each blood sample was analysed simultaneously.
The advantage of ROTEM® compared to plasma-based
conventional coagulation tests, such as APTT and INR, is
that ROTEM® is performed in whole blood and thereby, is
superior for reflection of in vivo coagulation. ROTEM® re-
sults are performed quickly, and the results are more suit-
able for targeted haemostatic treatment in bleeding
patients [32]. However, ROTEM® has a limited capability
to detect antithrombotic treatment, and as platelet func-
tion is not reflected in the ROTEM® analysis, it is import-
ant to supplement it with platelet aggregation tests such
as the Multiplate®Analyzer. The agonists used in the
present study were sensitive to the use of ADP inhibitors
and acetysalicylic acid [13]. Hence, the use of both these
Table 5 The difference in Multiplate®Analyzer measurements performed at 33 °C and 37 °C in 40 cardiac arrest patients
Hypothermia (body core temp median 33.1 °C), n = 39
33 °C versus 37 °C
Normothermia (body core temp median 37.5 °C), n = 37
33 °C versus 37 °C
Multiplate®Analyzer, (AU*min) Multiplate®Analyzer, (AU*min)
Mean difference (95 % CI) P value Mean difference (95 % CI) P value
COLtest®a –4 (–30; 23) 0.79 –62.0 (–87; –37) <0.001
TRAPtest® –38 (–96; 20) 0.19 –12.5 (–84; 59) 0.73
ASPItest®
Alla –24 (–83; 35) 0.43 –106 (–158; –53) <0.001
No aspirin (n = 9) –71 (–199; 57) 0.28 –176 (–336; –16) 0.03
Aspirin (n = 26) –27 (–53; –1) 0.04 –76 (–108; –45) <0.001
ADPtest®
No ADP inhibitors (n = 20) 106 (68; 144) <0.001 51 (18; 83) 0.003
ADP inhibitors (n = 18) 38 (6; 69) 0.02 2 (–33; 37) 0.92
temp temperature, n number, CI confidence interval, ADP inhibitors adenosine diphosphate receptor inhibitors, AU*min (y-axis is expressed in Aggregation units
(AU) and x-axis in minutes). aThe body core temperature significantly affected the differences in results at 33 °C and 37 °C
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two instruments increased the capability to investigate the
entire coagulation. However, none of the included
methods reflect the entire haemostatic process, as this also
includes vasoconstriction, endothelium function, and sig-
nificance of flow. Moreover, the relatively high imprecision
of these methods must be taken into consideration when
interpreting the results.
We tested whether the difference between samples
analysed at 33 °C and 37 °C were affected by the patient
being hypothemic or normothermic. Thus, the time-
frame between the hypothermic and the normothermic
blood sample meant that confounding was possible.
Potentially confounders were the “post cardiac arrest
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Fig. 2 Box plots of Multiplate®Analyzer results analysed at 33 °C and 37 °C. Forty cardiac arrest patients were included in the study. There were 39
hypothermic blood samples and 36 normothermic blood samples included in the Multiplate®Analyzer analyses. The p value is for comparison of the
results performed at 33 °C and at 37 °C
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causes inflammation and thereby, might stimulate
coagulation [33]. Suspicion of increased inflammation
between the hypothermic and the normothermic blood
sample is reinforced by increase in fibrinogen and CRP.
However, if the ROTEM® and Multiplate®Analyzer re-
sults were substantially influenced by inflammation, the
results from the present study would only be affected if
inflammation affected analyses performed at 33 °C and
37 °C unequally, but notably, this is not likely the case.
The use of unfractionated heparin or bivalirudin admin-
istered in relation to the percutaneous coronary inter-
vention could probably be neglected owing to the long
time frame between the administration of the drugs and
the blood sampling time.
The patients were treated with two different interven-
tions, namely 24 hours and 48 hours of targeted
temperature management. Comparing the ROTEM® and
Multiplate®Analyzer results in the two intervention groups,
we found deviating, non-conclusive signs of compromised
haemostasis in INTEM® in the 48-hour group. If we pre-
sume that prolonged targeted temperature management
influenced the 48-hour group, then there is a small risk
that we might have overlooked the impact of body core
temperature on the ROTEM® data analyses. Apart from
this small difference, ROTEM® and Multiplate®Analyzer re-
sults were comparable. We therefore found it reasonable
to combine the two interventions groups into one.
Conclusions
In conclusion, the present study suggested that ROTEM®
results are not sensitive to the patient’s body core
temperature. There was a small compromised initiation of
haemostasis when the analysis was performed at 33 °C, but
no difference in clot strength. It is questionable whether
this small difference is of clinical relevance. The analyses of
platelet aggregation were influenced by hypothermia in dif-
ferent ways depending on the agonist used and on whether
patients were hypothermic or normothermic.
Analysis of whole blood coagulation tests should be
performed at a temperature of 37 °C, irrespective of
whether the patient’s body core temperature is 33 °C or
37 °C.
Key messages
 Thromboelastometry and platelet aggregation tests
are used to evaluate bleeding patients, but the
analyses are performed at 37 °C, irrespective of the
patient’s body core temperature
 Thromboelastometry showed slightly compromised
initiation of haemostasis when analysed at 33 °C
compared with 37 °C, but no difference in clot
strength
 The platelet aggregation test was dependent on both
the temperature of the analyses and the body core
temperature
 The temperature of whole blood coagulation tests
should be kept at 37 °C, irrespective of whether the
patient’s body core temperature is 33 °C or 37 °C
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